TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Obesity Through Infancy Interventions
Brief Summary: Childhood obesity has reached epidemic proportions and its prevalence continues to rise, even among very young children. Because the current evidence base regarding potentially effective early intervention components to prevent obesity is so incomplete, it is logical to initiate obesity prevention intervention research during infancy, focusing on the two major components of the infant lifestyle, sleeping and feeding.


Options:
A: Arm Label: Essential Health Care (EHC) only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Arm Label: EHC + Micronutrient Powders; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Arm Label: EHC + BCC; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Behavioral: Mass media | Arm Label: EHC + BCC + Micronutrient powders; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: EHC + BCC; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient powders; Assigned to Arm(s): EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders, Essential Health Care (EHC) only
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Repeated Food Exposure | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing, Behavioral: Repeated Food Exposure | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Infant Sleeping and Soothing; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Repeated Food Exposure; Assigned to Arm(s): 2, 3
C: Arm Label: Doula; Type: EXPERIMENTAL; Interventions: Behavioral: Doula | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Doula; Assigned to Arm(s): Doula
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: ECD Group; Type: EXPERIMENTAL; Interventions: Behavioral: ECD | Arm Label: Enhanced Nutrition; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Nutrition | Arm Label: ECD and Enhanced Nutrition; Type: EXPERIMENTAL; Interventions: Behavioral: ECD, Behavioral: Enhanced Nutrition | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: ECD; Assigned to Arm(s): ECD Group, ECD and Enhanced Nutrition | Intervention Type: BEHAVIORAL; Name: Enhanced Nutrition; Assigned to Arm(s): ECD and Enhanced Nutrition, Enhanced Nutrition

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Obesity Through Infancy Interventions
Brief Summary: Childhood obesity has reached epidemic proportions and its prevalence continues to rise, even among very young children. Because the current evidence base regarding potentially effective early intervention components to prevent obesity is so incomplete, it is logical to initiate obesity prevention intervention research during infancy, focusing on the two major components of the infant lifestyle, sleeping and feeding.


Options:
A: Arm Label: BFHI steps 1-9; Type: EXPERIMENTAL; Interventions: Other: implementation of the Baby-Friendly Hospital Initiative | Arm Label: BFHI steps 1-9 +well-child clinic; Type: EXPERIMENTAL; Interventions: Other: BFHI steps 1-9 +well-child clinic | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: implementation of the Baby-Friendly Hospital Initiative; Assigned to Arm(s): BFHI steps 1-9 | Intervention Type: OTHER; Name: BFHI steps 1-9 +well-child clinic; Assigned to Arm(s): BFHI steps 1-9 +well-child clinic
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Repeated Food Exposure | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing, Behavioral: Repeated Food Exposure | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Infant Sleeping and Soothing; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Repeated Food Exposure; Assigned to Arm(s): 2, 3
C: Arm Label: Home-based counselling visits by volunteers; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based counselling | Arm Label: Standard care through existing health system; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based counselling; Assigned to Arm(s): Home-based counselling visits by volunteers
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Lactation Consultant | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Provider Prompt | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: LC+ Provider Prompt | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lactation Consultant; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Provider Prompt; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: LC+ Provider Prompt; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy
Brief Summary: The purpose of this trial is to determine whether a mucosa-to-mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate.


Options:
A: Arm Label: duct-to-mucosa; Type: EXPERIMENTAL; Interventions: Procedure: duct-to-mucosa, Device: Internal stent | Arm Label: invagination; Type: ACTIVE_COMPARATOR; Interventions: Procedure: invagination, Device: Internal stent | Intervention Type: PROCEDURE; Name: duct-to-mucosa; Assigned to Arm(s): duct-to-mucosa | Intervention Type: PROCEDURE; Name: invagination; Assigned to Arm(s): invagination | Intervention Type: DEVICE; Name: Internal stent; Assigned to Arm(s): duct-to-mucosa, invagination
B: Arm Label: one-layer duct-to-mucosa anastomosis; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Arm Label: two-layer duct-to-mucosa anastomosis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): one-layer duct-to-mucosa anastomosis, two-layer duct-to-mucosa anastomosis
C: Arm Label: Mucosa-to-jejunal mucosa technique of pancreaticojejunosto; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): Mucosa-to-jejunal mucosa technique of pancreaticojejunosto
D: Arm Label: horizontal mattress; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy with horizontal mattress suture | Arm Label: interrupted suture; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy with interrupted suture | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy with horizontal mattress suture; Assigned to Arm(s): horizontal mattress | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy with interrupted suture; Assigned to Arm(s): interrupted suture

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone
Brief Summary: The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.


Options:
A: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
B: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
C: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy
D: Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard medical therapy | Arm Label: endovascular + standard medical therapy; Type: EXPERIMENTAL; Interventions: Device: endovascular treatment, Other: standard medical therapy | Intervention Type: DEVICE; Name: endovascular treatment; Assigned to Arm(s): endovascular + standard medical therapy | Intervention Type: OTHER; Name: standard medical therapy; Assigned to Arm(s): endovascular + standard medical therapy, standard medical therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone
Brief Summary: The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.


Options:
A: Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Solitaire FR device | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: DEVICE; Name: Solitaire FR device; Assigned to Arm(s): Endovascular treatment | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical treatment
B: Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Arm Label: IV rtPA and IA Penumbra System; Type: EXPERIMENTAL; Interventions: Device: Penumbra System | Intervention Type: DRUG; Name: intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV rtPA | Intervention Type: DEVICE; Name: Penumbra System; Assigned to Arm(s): IV rtPA and IA Penumbra System
C: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
D: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone
Brief Summary: The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.


Options:
A: Arm Label: Sedation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sedation, Procedure: Intra-arterial Thrombectomy | Arm Label: General Anesthesia; Type: ACTIVE_COMPARATOR; Interventions: Drug: General Anesthesia (GA), Procedure: Intra-arterial Thrombectomy | Intervention Type: DRUG; Name: Sedation; Assigned to Arm(s): Sedation | Intervention Type: DRUG; Name: General Anesthesia (GA); Assigned to Arm(s): General Anesthesia | Intervention Type: PROCEDURE; Name: Intra-arterial Thrombectomy; Assigned to Arm(s): General Anesthesia, Sedation
B: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
D: Arm Label: General anaesthesia; Type: ACTIVE_COMPARATOR; Interventions: Procedure: General anaesthesia | Arm Label: Conscious Sedation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conscious Sedation | Intervention Type: PROCEDURE; Name: General anaesthesia; Assigned to Arm(s): General anaesthesia | Intervention Type: PROCEDURE; Name: Conscious Sedation; Assigned to Arm(s): Conscious Sedation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone
Brief Summary: The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
D: Arm Label: Solitaire™ FR device; Type: N/A; Interventions: Device: Solitaire™ FR device | Intervention Type: DEVICE; Name: Solitaire™ FR device; Assigned to Arm(s): Solitaire™ FR device

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone
Brief Summary: The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2
B: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: tenecteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tissue plasminogen activator, tPA | Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tissue plasminogen activator, tPA; Assigned to Arm(s): 2
D: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.
Brief Summary: Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites.

Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites.

The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).


Options:
A: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone and furosemide | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone and furosemide | Intervention Type: DRUG; Name: Spironolactone and furosemide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Spironolactone and furosemide; Assigned to Arm(s): A, B
D: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy
Brief Summary: To compare palonosetron with granisetron hydrochloride as a control in the efficacy of intravenous single dose in preventing acute and delayed gastro-intestinal disorders, such as nausea and vomiting induced by highly emetogenic chemotherapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: palonosetron | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: granisetron hydrochloride | Intervention Type: DRUG; Name: palonosetron; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: granisetron hydrochloride; Assigned to Arm(s): 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Emend | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Emend; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: metoclopramide | Arm Label: dexamethason; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethason | Arm Label: palonosetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: palonosetron | Intervention Type: DRUG; Name: metoclopramide; Assigned to Arm(s): metoclopramide | Intervention Type: DRUG; Name: dexamethason; Assigned to Arm(s): dexamethason | Intervention Type: DRUG; Name: palonosetron; Assigned to Arm(s): palonosetron
D: Arm Label: SCH 619734 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 1 | Arm Label: SCH 619734 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 2 | Arm Label: SCH 619734 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 3 | Arm Label: SCH 619734 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: SCH 619734 Dose 4 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SCH 619734 Dose 1; Assigned to Arm(s): SCH 619734 Dose 1 | Intervention Type: DRUG; Name: SCH 619734 Dose 2; Assigned to Arm(s): SCH 619734 Dose 2 | Intervention Type: DRUG; Name: SCH 619734 Dose 3; Assigned to Arm(s): SCH 619734 Dose 3 | Intervention Type: DRUG; Name: SCH 619734 Dose 4; Assigned to Arm(s): SCH 619734 Dose 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A